Want to see SRTS full AI Analyst Report?
Top Page
Sensus Healthcare
(NASDAQ:SRTS)
Select Model
Select Model
Rating:47Neutral
Price Target:
$3.00
▼(-0.99% Downside)
Action:Reiterated
Date:08/21/26
SRTS scores low primarily due to sharply weaker profitability and renewed cash burn, which outweigh the benefit of low leverage. Technical indicators are mostly neutral with the stock still below longer-term trend levels, and valuation is unattractive because the company is currently loss-making with no dividend support. Earnings-call catalysts (CPT-driven demand and Q3 revenue timing benefit) provide some upside potential but remain execution-dependent.
Positive Factors
Very low leverage
Minimal leverage reduces solvency risk and preserves financial flexibility while the company works through operating losses. A lightly indebted balance sheet may support continued investment and limit interest-related pressure if revenue recovers.
Negative Factors
Sharp revenue and unit-sales contraction
The decline indicates materially weaker demand conversion and reduced operating scale. Sustained lower equipment volume would limit fixed-cost absorption, weaken customer acquisition efficiency, and make the recovery dependent on successfully converting the newer pipeline.
Read all positive and negative factors
Positive Factors
Negative Factors
Very low leverage
Minimal leverage reduces solvency risk and preserves financial flexibility while the company works through operating losses. A lightly indebted balance sheet may support continued investment and limit interest-related pressure if revenue recovers.
Read all positive factors
Sensus Healthcare Key Performance Indicators (KPIs)
Any
Revenue by Geography
Breaks down revenue across regions to show where Sensus earns its sales. For this small med‑tech firm, the split reveals dependence on key markets (and associated reimbursement or regulatory risk), highlights where expansion is succeeding, and signals how diversified the company’s growth prospects are.
Breaks down revenue across regions to show where Sensus earns its sales. For this small med‑tech firm, the split reveals dependence on key markets (and associated reimbursement or regulatory risk), highlights where expansion is succeeding, and signals how diversified the company’s growth prospects are.
Data provided by:
The Fly
The FlySensus Healthcare (SRTS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$54.98M
Dividend YieldN/A
Average Volume (3M)29.79K
Price to Earnings (P/E)―
Beta (1Y)0.51
Revenue Growth-53.40%
EPS Growth-1719.88%
CountryUS
Employees60
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.94
Shares Outstanding16,462,059
10 Day Avg. Volume20,529
30 Day Avg. Volume29,789
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.35
Price to Sales (P/S)2.36
P/FCF Ratio195.73
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.17Price Target Upside70.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.42
Revenue Forecast (FY)$21.99M
Sensus Healthcare Business Overview & Revenue Model
Company Description
Sensus Healthcare, Inc. operates as a medical technology enterprise, manufacturing and distributing radiation therapy apparatuses to medical institutions across the globe. The company's portfolio leverages superficial radiation therapy (SRT), a cu...
How the Company Makes Money
Sensus Healthcare primarily generates revenue by selling its superficial radiotherapy systems to medical practices and clinics. In addition to capital equipment sales, the company earns recurring and ancillary revenue from system-related items and...
Sensus Healthcare Earnings Call Summary
Earnings Call Date:Aug 13, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Oct 29, 2026
Earnings Call Sentiment Negative
The call contained mixed operational positives — a strengthened pipeline, broader customer interest driven by new CPT codes, increasing Sensus Link adoption, and a clarified path for the eight delayed units to contribute to Q3 revenue. However, these commercial positives were overshadowed by steep year-over-year financial deterioration: a ~68.5% revenue decline, a significantly larger GAAP net loss ($8.7M vs $1.0M prior year) including a $5.7M valuation allowance, worsening adjusted EBITDA, declining other income, and inventory build with lower cash. Given the material financial setbacks in the quarter despite constructive commercial momentum and an expected H2 recovery, the net picture is negative.Positive Updates
Pipeline and Commercial Momentum Strengthened
Management reports a materially stronger commercial pipeline in H2 2026 driven by physician education around new CPT codes, increased inbound interest, and engagement with larger physician groups and health systems. They stated the pipeline includes both new customers and multi-location opportunities that could drive recurring and scalable adoption.
Negative Updates
Sharp Revenue Decline
Revenue fell to $2.3M in Q2 2026 from $7.3M in Q2 2025 — a decrease of approximately $5.0M or ~68.5% year-over-year, driven primarily by fewer units sold (11 units vs 19 units prior-year).
Read all updates
Q2-2026 Updates
Positive
Negative
Pipeline and Commercial Momentum Strengthened
Management reports a materially stronger commercial pipeline in H2 2026 driven by physician education around new CPT codes, increased inbound interest, and engagement with larger physician groups and health systems. They stated the pipeline includes both new customers and multi-location opportunities that could drive recurring and scalable adoption.
Read all positive updates
Company Guidance
The guidance emphasized a stronger second half driven by conversion of a beefed-up pipeline and recognition of eight units (previously delayed by financing) that moved revenue into Q3; management noted Q2 revenue was $2.3M (vs. $7.3M a year ago) on 11 units sold (would have been 19), following 14 units in Q1, and said those eight units carry an ASP near $250K each. Key Q2 metrics: cost of sales $1.5M, gross profit ~$0.8M and gross margin 34.8%, G&A $1.8M, selling & marketing $1.1M, R&D $1.1M, adjusted EBITDA -$3.0M, net loss $8.7M (-$0.53/share) including a $5.7M deferred tax valuation allowance, cash $15.2M (down from $18.3M), inventory $18.4M, and no outstanding revolving borrowings; management expects continued mix of ~50/50 recurring (rentals/Fair Deal) and outright purchases, rising Sensus Link activations, and international growth (notably Australia/APAC) with the company focused on converting opportunities to drive improved H2 performance.Sensus Healthcare Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
78
Positive
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 17.51M | 27.48M | 41.81M | 24.41M | 44.53M | 27.04M |
| Gross Profit | 6.37M | 11.87M | 24.43M | 14.06M | 29.63M | 16.99M |
| EBITDA | -9.50M | -9.24M | 9.45M | 1.11M | 28.50M | 4.73M |
| Net Income | -15.48M | -7.72M | 6.65M | 485.00K | 24.24M | 4.12M |
Balance Sheet | ||||||
| Total Assets | 41.26M | 53.04M | 62.16M | 53.71M | 56.73M | 32.24M |
| Cash, Cash Equivalents and Short-Term Investments | 15.19M | 22.08M | 22.06M | 23.15M | 25.52M | 14.52M |
| Total Debt | 343.00K | 680.00K | 602.00K | 783.00K | 1.02M | 225.00K |
| Total Liabilities | 4.40M | 4.94M | 6.34M | 4.87M | 8.67M | 6.22M |
| Stockholders Equity | 36.86M | 48.10M | 55.83M | 48.84M | 48.07M | 26.02M |
Cash Flow | ||||||
| Free Cash Flow | -6.96M | 332.00K | -1.11M | -2.37M | -1.57M | -414.00K |
| Operating Cash Flow | -6.80M | 528.00K | -831.00K | -2.15M | -1.41M | -286.00K |
| Investing Cash Flow | -173.00K | -196.00K | -276.00K | -187.00K | 14.84M | 129.00K |
| Financing Cash Flow | -5.00K | -305.00K | 15.00K | -40.00K | -2.43M | -231.00K |
Sensus Healthcare Technical Analysis
Positive
3.03
Price Trends
2.98
Positive
3.33
Positive
3.79
Negative
Market Momentum
0.04
Negative
65.45
Neutral
72.72
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SRTS, the sentiment is Positive. The current price of 3.03 is above the 20-day moving average (MA) of 3.02, above the 50-day MA of 2.98, and below the 200-day MA of 3.79, indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 65.45 is Neutral, neither overbought nor oversold. The STOCH value of 72.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SRTS.
Sensus Healthcare Risk Analysis
Sensus Healthcare disclosed 24 risk factors in its most recent earnings report. Sensus Healthcare reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Sensus Healthcare Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $865.66M | 12.05 | 11.80% | ― | -6.71% | -50.25% | |
70 Outperform | $12.81B | 79.51 | 11.09% | ― | 17.55% | 7.09% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $54.98M | -3.56 | -34.09% | ― | -53.40% | -1719.88% | |
46 Neutral | $67.58M | -0.75 | -51.88% | ― | 25.74% | -26.25% | |
44 Neutral | $13.28M | -3.72 | -64.23% | ― | 3.68% | 36.91% | |
43 Neutral | $33.56M | -0.70 | -99.04% | ― | -12.34% | -2363.03% |
* Healthcare Sector Average
SRTS
Sensus Healthcare
3.34
0.21
6.71%
ARAY
Accuray
0.28
-1.27
-81.87%
IRIX
Iridex
0.76
-0.51
-40.47%
PEN
Penumbra
325.18
61.01
23.09%
INMD
InMode
15.06
0.49
3.36%
NNOX
Nano-X Imaging
0.86
-3.03
-77.92%
Sensus Healthcare Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Sensus Healthcare Secures New $15 Million Credit Facility
Positive
Jun 5, 2026
On June 2, 2026, Sensus Healthcare, Inc. entered into a new revolving credit facility with City National Bank of Florida for up to $15 million, replacing a prior facility that had been terminated. The loan, maturing June 5, 2027, bears interest at...
Executive/Board ChangesShareholder Meetings
Sensus Healthcare Shareholders Back Board, Pay, and Auditor
Positive
Jun 2, 2026
At Sensus Healthcare, Inc.’s Annual Meeting of Stockholders held on May 29, 2026, shareholders re-elected incumbent directors Eric Sachetta and Michael J. Sardano as Class II directors to new three-year terms expiring in 2029, reinforcing co...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.